logo
Why Did Oklo Stock Drop Today?

Why Did Oklo Stock Drop Today?

Yahoo3 days ago
Cantor Fitzgerald initiated coverage of Oklo stock with an overweight rating today.
Oklo also announced it will hire Kiewit Nuclear Solutions Co. to help build its first commercial reactor.
Things are progressing at Oklo, but the stock costs quite a lot and has no revenue.
10 stocks we like better than Oklo ›
Shares of small nuclear reactor-builder Oklo (NYSE: OKLO) tumbled 3.1% through 12:10 p.m. ET Tuesday. Curiously, the news on Oklo today is good, not bad.
Cantor Fitzgerald initiated coverage of Oklo stock with an overweight rating and a $73 price target. No sooner had it done so than Oklo announced it has picked Kiewit Nuclear Solutions Co. to help build its first commercial Aurora powerhouse in Idaho, at Idaho National Laboratory (INL).
Let's start with the initiation. As The Fly relates, Cantor is calling Oklo key to a global transition to safe nuclear energy. The company's small module reactor technology relies on "proven" fast fission reactors, which should help with Nuclear Regulatory Commission approvals. Cantor expects Oklo to become a "big winner" in the transition to nuclear energy.
Moving next to the INL announcement, Oklo says "pre-construction" work on its new reactor will begin later this year, and "commercial operations [are] targeted for late 2027 to early 2028." Importantly, Oklo also confirmed that it has secured access to the uranium fuel it will need to operate the reactor, and is making "regulatory progress" toward getting it design approved.
And yet, investors don't seem to be buying the argument -- or the stock, at least not today. Why not?
Valuation's probably one concern. Oklo stock costs $9.2 billion, yet the company has neither profit not even revenue on which to hang a valuation. While analysts do expect revenue to begin in 2027, in line with the "commercial operations" forecast, profits won't arrive until 2030 at the earliest.
It's hard to value a stock with so many unknowns, lasting so many years into the future. And it's hard to call Oklo stock a buy because of this.
Before you buy stock in Oklo, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oklo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $680,559!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,670!*
Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Did Oklo Stock Drop Today? was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025

Yahoo

time26 minutes ago

  • Yahoo

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a rare blood disorder. In the first quarter, Reblozyl generated $478 million in sales, marking a 35% increase compared to the same period last year. Bristol-Myers Squibb Company (NYSE:BMY)'s revenue for the year came in at $11.2 billion, which, though, fell by 5.6% from the same period last year, beat analysts' estimates by $494.6 million. The company's cash position also remained strong, with cash and cash equivalents of $10.9 billion, up from $10.34 billion at the end of December 2024. Bristol-Myers Squibb Company (NYSE:BMY) has raised its full-year revenue forecast from around $45.5 billion to a new range of about $45.8 billion to $46.8 billion. This upward revision reflects strong results from its Growth Portfolio, stronger-than-anticipated Legacy Portfolio sales in the first quarter of 2025, and a positive foreign exchange impact of roughly $500 million. Bristol-Myers Squibb Company (NYSE:BMY) offers a quarterly dividend of $0.62 per share and has a dividend yield of 5.18%, as of July 17. The company has been rewarding its shareholders with growing dividends for the past 16 years. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts

Yahoo

time26 minutes ago

  • Yahoo

How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent years, Abbott Laboratories (NYSE:ABT)'s diabetes care division has emerged as its strongest growth engine, thanks largely to its continuous glucose monitoring (CGM) product line, FreeStyle Libre. According to the company, FreeStyle Libre has achieved record-breaking dollar sales, making it the most successful medical device in history. Despite this milestone, significant room for growth remains, as a large number of diabetics worldwide have yet to adopt CGM technology, despite its clear benefits. In addition, Abbott Laboratories (NYSE:ABT) holds the status of a Dividend King with 53 consecutive years of dividend growth under its belt. The company has grown its dividend payouts by nearly 146% over the past ten years. With a business model designed for durability, the company is seen as a reliable option for investors seeking steady dividend growth in the years ahead. It currently offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.95%, as of July 17. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025?
Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025?

Yahoo

time26 minutes ago

  • Yahoo

Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025?

McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy. In its fourth-quarter 2025 earnings announcement, the company revealed plans to spin off its Medical-Surgical Solutions segment into a separate entity, referred to as 'NewCo.' Management emphasized that disciplined portfolio management remains a core element of its overall strategy. McKesson stated that this separation is expected to strengthen the strategic direction and operational focus of both businesses, while also delivering greater value to shareholders. McKesson Corporation (NYSE:MCK)'s cash position came in strong in fiscal 2025. Over the full fiscal year, the company returned $3.5 billion to its shareholders, comprising $3.1 billion in share buybacks and $345 million in dividends. It reported $6.1 billion in cash flow from operations and allocated $859 million toward capital expenditures, leading to a free cash flow of $5.2 billion. McKesson Corporation (NYSE:MCK) has been growing its payouts for eight consecutive years, and in the past five years, its dividend growth came in at nearly 12%. The company currently offers a quarterly dividend of $0.71 per share and has a dividend yield of 0.40%, as of July 17. While we acknowledge the potential of MCK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store